Novo Nordisk vs. Genentech
Executive Summary
Patent litigation relating to human growth hormone and insulin settled out of court, the companies announce June 29. Novo and Genentech will cross-license certain patents relating to human growth hormone. Beginning at the end of August, Novo will also receive a worldwide license under Genentech patents relating to insulin and Genentech will receive payments from Novo